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Abstract
Background: Recurrent nightmares can effectively be treated with cognitive-behavioral techniques such as imagery
rehearsal therapy, which involves imagery rescripting (IR) of nightmares, and imaginal exposure (IE) therapy. However,
the underlying mechanisms of these treatments remain largely unknown. To investigate this, we identified a number
of variables that might mediate the therapeutic effect of rescripting-based and/or exposure-based therapies. Also, to
control for the possible confounding influence of (other) treatment components, we designed two stripped-down
treatment protocols, which primarily consist of either (1) rescripting of, or (2) exposure to, the nightmare content. In a
randomized controlled trial, we aim to investigate the therapeutic efficacy of these stripped-down IR and IE treatments,
and explore their working mechanisms.
Method: Three weekly sessions of either IR or IE will be compared to a waiting-list control group. Ninety participants
suffering from nightmare disorder will be included and randomly allocated to one of the three groups. The primary
clinical outcome measures are nightmare frequency and distress caused by nightmares. Secondary clinical outcome
measures include sleep complaints, dysfunctional beliefs about nightmares, and posttraumatic stress symptom severity.
Outcomes will be assessed weekly from week 1 (pre-assessment) to week 5 (post-assessment). Online follow-up
assessments will take place at 3 and 6 months after post-assessment. In order to investigate temporal relationships
between mediators and outcome, we will measure the proposed mediators of the treatment effect 1 day after each
outcome assessment (but not after the follow-ups). Mediators include nightmare distress and valence, mastery of the
nightmare content, predictability, controllability, and tolerability of emotions elicited by nightmares, as well as sleep
quality.
Discussion: The proposed trial allows us to investigate the efficacy of IR and IE as intervention techniques for the
treatment of nightmares, and to explore mediators of their respective therapeutic effects. The results may advance
our understanding of nightmare therapies by identifying possible mechanisms of psychological treatments for
chronic nightmares. Moreover, the results of the proposed study might provide useful knowledge about the
working mechanism of rescripting-based and exposure-based treatments in general.
Trial registration: Netherlands Trial Register (NTR4951), registered on 14 December 2014.
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Background
According to the fifth edition of the Diagnostic and
Statistical Manual of Mental Disorders (DSM-5; [1]),
nightmares are defined as extremely dysphoric dreams
that typically involve threats to an individual’s survival
and/or someone’s emotional or physical sense of safety,
and they usually awaken the individual from sleep. Upon
awakening, the individual quickly becomes alert and con-
scious of their surroundings. To qualify for the diagnosis
“nightmare disorder,” nightmares need to cause substan-
tial daytime suffering and distress. Typically, they are also
accompanied by disrupted sleep and affective complaints.
Furthermore, nightmares are often associated with various
forms of psychopathology such as anxiety, depression,
posttraumatic stress disorder (PTSD), suicidal ideation,
substance abuse, and personality disorders [2–4].
The prevalence of nightmare disorder is high, with ap-
proximately 2–5 % of the general population suffering
from one or more nightmares per week [5–7]. In a psychi-
atric sample, the prevalence rate was found to be much
higher, with up to 30 % of patients suffering from night-
mare disorder [8].
Several cognitive-behavioral therapy (CBT) techniques ef-
fectively ameliorate nightmare symptoms (for a review, see
[3, 9]). To date, imagery rehearsal therapy (IRT) is the most
empirically supported treatment for nightmares [9–11]. In
IRT, patients are encouraged to change (rescript) the story-
line of a nightmare into an alternative and less distressing
story, which they then rehearse in their imagination (e.g.,
[12]). IRT can successfully decrease nightmare frequency
and distress [10, 11], and it improves sleep quality [13, 14].
Next to IRT, exposure techniques are also effective in the
treatment of nightmares. In imaginal exposure (IE) for
nightmares, patients are confronted with and exposed to
the content of their nightmares. Exposure-based treatment
techniques have produced favorable changes in nightmare
frequency and intensity in face-to-face [15, 16] and self-
help formats [17–19].
Even though exposure-based and rescripting-based tech-
niques both seem to be effective treatments for nightmares,
there is an ongoing debate regarding the working mecha-
nism of psychological treatments for chronic nightmares
(see [11]). It has been argued that IRT and exposure may
work via different pathways, since the techniques follow
substantially different procedures. However, the working
mechanisms of IRT and exposure for nightmares have
not yet systematically been studied and, therefore, remain
largely unknown. Thus, more research into the mecha-
nisms of change in nightmare treatments is needed.
One way to gather knowledge about the working mech-
anisms of therapeutic techniques is to study variables that
mediate treatment outcome [20, 21]. Such mediators are
variables that may explain the relationship between an in-
dependent (e.g., treatment type) and a dependent variable
(e.g., clinical outcome). Although mediators might not
explicitly explain how behavior change occurs, they may
uncover critical processes about why such change occurs
[21]. Therefore, to further our understanding of the work-
ing of psychological nightmare treatments, the proposed
study aims to investigate potential mediators of exposure-
based and rescripting-based nightmare therapies. Possible
mediators of the treatment effect are selected based on
previous theoretical and empirical knowledge about ex-
posure and rescripting treatments and/or their working
mechanisms across psychological disorders.
Mechanisms of change
Traditional theories of exposure therapy suggest that in
order for the technique to be effective, exposure to a given
stimulus needs to continue until the fear elicited by the
stimulus eventually decreases. Within this emotional pro-
cessing framework [22, 23], it is proposed that fear reduction
(i.e., reduction in Subjective Units of Distress; SUDs) during
and/or across exposure trials is a critical index of therapeutic
change (but see [24] for a critical discussion of emotional
processing theory). However, more contemporary models of
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exposure therapy do not emphasize fear reduction during or
across exposure trials per se, but rather focus on other
underlying processes. For example, inhibitory learning
models of exposure therapy (e.g., [25, 26]) state that fear
extinction (a laboratory analog for exposure therapy; [27])
does not erase a previously learned association between a
stimulus (conditioned stimulus, CS) and an aversive event
(unconditioned stimulus, US), but that it involves the for-
mation of a new (inhibitory) memory (CS-noUS) while
leaving the original fear memory (CS-US) intact [25,
28]. Inhibitory learning can be facilitated by certain pro-
cesses that are assumed to be critical to successful exposure
therapy [28], such as fear toleration [24]. While it is con-
sidered dysfunctional to down-regulate negative emotions
through suppression or avoidance [24], experiencing the
ability to tolerate such negative emotions during exposure
(which is incompatible with the original fear memory)
could stimulate new inhibitory learning [29]. In support of
this proposition, it has been shown that lower tolerance of
emotional distress is associated with higher PTSD symptom
severity [30]. Moreover, avoidance of negative emotional
states predicts severity of fear responding [31], whereas
acceptance of negative emotions reduces distress [32].
Other variables that are often linked to extinction lear-
ning and exposure therapy include the controllability
and/or predictability of aversive events [33]. The degree
to which people perceive certain events to be within their
control has long been suggested to be a fundamental
mediator of psychopathology and treatment [34]. The sig-
nificance of perceived controllability/predictability of aver-
sive outcomes has, therefore, been acknowledged in
numerous psychotherapy models (e.g., [35, 36]) as well as
modern fear-learning theories (e.g., [37, 38]). Importantly,
it has been proposed that not only uncontrollable aversive
events, but also unexpected bursts of emotions may facili-
tate the development of anxiety disorders [35]. With
regard to nightmares, the latter might be especially rele-
vant, as patients regularly experience strong negative (and
often fearful) emotions in response to their dreams. Thus,
perceived controllability and/or predictability of harm
(i.e., negative emotions as a result of nightmares) might be
important variables in the treatment of nightmares. Though
predictability/controllability of harmful events has foremost
been associated with exposure therapy (e.g., [33]), it might
also play an essential role in rescripting treatments. More
specifically, in most rescripting-based therapeutic tech-
niques, patients are encouraged to change a negative event
according to their individual emotional needs. Hence, it
can be assumed that patients gain control about the
emotions they experience in response to a certain aversive
event (e.g., nightmares). Therefore, we argue that control-
lability and/or predictability of emotions elicited by night-
mares might be critical mediating variables in both IE
and IR.
Even though empirical evidence regarding the under-
lying working mechanism of imagery rescripting (IR) is
still limited, Arntz [39] recently proposed that IR might
change the meaning of emotional events or memories
through US devaluation, a process where fear memories or
other aversive stimuli are degraded by changing the negative
valence of such stimuli. There is preliminary evidence for
the involvement of US devaluation in IR [40, 41], yet more
research is needed to determine whether stimulus devalu-
ation is a crucial mechanism for the efficacy of IR. Another
variable that seems to play an important role in IR is mas-
tery or self-efficacy. Research about IR for posttraumatic
nightmares suggests that IR works by influencing negative
beliefs about self-ability and the ability to control distressing
images [42]. On a similar note, Krakow et al. [14] and
Germain et al. [43] have argued that altering nightmares
through IR techniques improves patients’ perceived mas-
tery of nightmares (see also [11]). The hypothesis that
increased mastery explains the effects of IR might be
related to older explanations of IR, which emphasize the
healing properties of expressing inhibited responses
(see [39]). A key characteristic of nightmares is the inhi-
bition of action tendencies in the dream, fuelled by the
inability to control the muscles because of sleep paralysis,
which leads to feelings of powerlessness and uncontrolla-
bility. By expressing these inhibited responses in the new
script (e.g., attacking the perpetrator, successfully escaping
from a dangerous situation, etc.) a feeling of mastery could
be reestablished. Thus, mastery of the nightmare content
might be an index of therapeutic change in IR.
Based on the above-mentioned theories and empirical
findings, we identified the following variables as possible
mediators of change for the treatment effect of IR and IE
for recurrent nightmares: (1) nightmare valence, (2) pre-
dictability, (3) controllability, and (4) tolerability of emo-
tions elicited by nightmares, (5) mastery of the nightmare
content, and (6) reduction in SUDs. In addition, negative
consequences of nightmares (i.e., distress caused by night-
mares at night and during the day) are hypothesized to be
a determining factor for nightmares to become recurrent
and problematic [44]. Such nightmare distress (7) might,
therefore, be an important mediator of the treatment ef-
fect for any nightmare therapy. Finally, we included sleep
quality (8) in the set of proposed mediators for the treat-
ment effect of IR and IE, as sleep plays a crucial role in
the consolidation and reconsolidation of memories [45].
Trial objectives
Investigating the role of these mediators in current night-
mare therapies poses a methodological challenge, mainly
because the treatments used to date consist of multiple
treatment components. Even though IR [46, 47] and imagi-
nal confrontation to the nightmare content [11] have been
identified as the principal components of rescripting-based
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and exposure-based treatments, respectively, themostwidely
used formats of IRT and imaginal exposure for nightmares
also incorporate nonspecific treatment modules. For ex-
ample, IRT usually comprises rescripting and rehearsal exer-
cises but also nightmare journals, safe place exercises as well
as discussions of the nightmare content (i.e., exposure to the
nightmare content; [12, 48, 49]). Similarly, exposure treat-
ments often include imaginal safe place and/or relaxation
exercises (e.g., [17]). Sometimes, exposure and rescripting
are even directly combined ([42, 50, 51]). In sum,most night-
mare treatments consist of amultitude of different treatment
methods and components. Given that different treatment
modules might target different types of symptoms [11], it re-
mains challenging to extract the exclusive working of
rescripting-based and exposure-based components within
these treatments.
Against this background, we designed and developed
treatment protocols, which consist mainly of either
rescripting of, or exposure to, the nightmare content.
Such stripped-down versions of exposure and rescripting
for nightmares allow us to investigate the therapeutic
efficacy of these treatments without any (possibly distor-
ting) influence of nonspecific treatment components. While
knowledge about the efficacy of pure rescripting and expo-
sure for nightmares might be valuable to appraise the
importance of different processes underlying psychological
treatments for chronic nightmares, stripped-down treat-
ment protocols have another significant advantage. Namely,
using stripped-down versions of IE and IR in the treatment
of nightmares may help to identify their mediating mecha-
nisms. Thus, in order to (1) identify mediators of the treat-
ment effect that (uniquely) contribute to the efficacy of
IE versus IR, we aim to (2) establish the efficacy of each
of these stripped-down treatments when compared to a
waiting-list control group. In line with previous research,
it is hypothesized that both treatments will effectively
reduce nightmare symptoms [10, 11]. Potential differences
between IR and IE will be explored. With regard to the
mechanisms of change, we assume that both treatments
target different key processes. This assumption is mainly
based on current theories about the working mechanisms
of IR and IE for nightmares. Specifically, we hypothesize
that nightmare distress and tolerability of emotions elic-
ited by nightmares might be critical mediating variables of
the treatment effect of IE. In contrast, nightmare valence
and mastery of the nightmare content might be parti-
cularly important mediators of the treatment effect in IR.
However, given the limited empirical knowledge about
the underlying mechanisms of nightmare treatments
(especially IR), we cannot exclude the possibility that a
number of the selected mediators might play a critical role
in both treatments (e.g., predictability and controllability
of emotions elicited by nightmares, and sleep quality),
rather than being exclusive to either IR or IE. Therefore,
we will further explore if the proposed variables play a
unique role in either rescripting-based or exposure-based
nightmare treatments, or whether they could be relevant
mediators of therapeutic change in both therapies.
Method
Design
In this single-center randomized controlled trial (RCT)
with three parallel groups, IR1 and IE therapy will be com-
pared to a waiting-list control (WL) group. Participants are
randomly allocated to one of three conditions: (1) IR, (2)
IE, or (3) a WL condition, stratified by PTSD diagnosis.
Participants in the WL condition receive one of the active
treatments after a 5-week waiting period. The proposed
mediators of change of the treatment effect will be explored
in both therapies. For an overview of the proposed flow of
participants, see Fig. 1. The present study protocol was
written in accordance with the SPIRIT 2013 guidelines
([52, 53]; see Additional file 1 for an overview of the check-
list items).
Sample size
The proposed study was powered to detect differences
between the treatments (i.e., IR and IE) compared to the
WL condition. A power calculation (two-sided, power =
80 %, alpha = 0.05; G*Power 3.1) with a medium to large
effect size for individual nightmare therapy (d = .74; [10])
showed that 30 participants in each condition would
suffice to detect a statistically significant difference
between each of the two treatment conditions and the
WL condition. Thus, a total of 90 participants will be
included in the proposed study and potential dropouts will
be replaced.
Eligibility criteria
Participants above the age of 18 will be included if they
meet the following criteria: DSM-5 diagnosis of idiopathic
and/or posttraumatic nightmare disorder [1]; one or more
nightmare(s) per week; the nightmares have a recurrent
(emotional) theme; and sufficient knowledge of the Dutch
language. Exclusion criteria are: a current diagnosis of
alcohol and/or drug abuse or dependency; PTSD resulting
from protracted and recurring trauma (type 2 trauma);
a current diagnosis of psychotic disorder; CBT-based
psychotherapy for nightmare symptoms in the preceding
12 months; and unstable medication intake. Comorbidity
as such will not be a reason for exclusion, but nightmare
disorder must be the principal diagnosis. If applicable,
participants will be asked to keep their medication intake
stable during and 4–8 weeks before treatment (depending
on the type of medication).
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Procedure
Participants will be recruited by means of advertisements
in online social networks (i.e., Facebook, Twitter), a public
website, and local newspaper announcements. Potential
participants visit the information website where they will
be provided with information about the trial, procedures,
randomization process, confidentiality, and contact details.
Interested participants fill out an online consent form and
preliminary online screener, which assesses basic inclusion
and exclusion criteria (e.g., availability of the participant,
nightmare frequency and distress, as well as alcohol and
drug intake). Based on this screener, eligible participants
will be telephoned for a short interview, which aims at
assessing nightmare symptoms, participant availability, pos-
sible medication intake, and differential diagnoses (e.g.,
pavor nocturnus). If participants appear to qualify for par-
ticipation, they will be invited for a face-to-face intake inter-
view. During the interview, a baseline (pre-)assessment of
all outcome measures will take place. Then, written in-
formed consent will be obtained from the participants and a
member of the research team assesses each participant’s eli-
gibility against all inclusion and exclusion criteria. Those
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Treatment Session 2 and outcome assessment
Treatment Session 3 and outcome assessment
Post-assessment
6-month online follow-up assessment
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Fig. 1 Proposed flow of participants. T1 = Pre-assessment, T2 =Week 1, T3 = Week 2, T4 = Week 3, T5 = Post-assessment, F1 = 3-month follow-up,
F2 = 6-month follow-up
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who are not eligible for participation will receive an email
outlining the reasons for exclusion. Participants who are eli-
gible for participation will be randomly assigned to one of
three conditions (i.e., IR, IE, or a WL control condition),
and they will be notified of the randomization outcome via
email or by telephone. To minimize the effects of knowledge
about the treatment on all outcome measures and media-
tors, participants will only be informed that they are being
allocated to “one of the treatment conditions” or “the
waiting-list condition”, while the name (and nature) of the
treatment is not communicated to them.
One week after baseline assessment, participants will re-
ceive the first of three treatment sessions (separated by at
least 7 days). In the beginning of each treatment session,
participants will be asked to fill out the primary treatment
outcome measures (for an overview of the assessments,
see Table 1). One week after the last treatment session or
after a 4-week waiting period, post-assessment will take
place. In order to ensure objective assessment of the treat-
ment effect, an independent assessor, who is blind to the
participants’ condition, will conduct the assessment. Pro-
posed mediators of the treatment effect will be assessed by
means of online questionnaires, which are sent via auto-
mated emails 1 day after pre- and post-assessment and after
each treatment session. For participants in the WL condi-
tion, the online mediator questionnaires are sent 1 day after
pre- and post-assessment, and once weekly during the wait-
ing period (separated by 7 days). All face-to-face
assessments and therapy sessions will take place at the
outpatient psychotherapeutic clinic (PsyPoli) of the Depart-
ment of Clinical Psychology at the UvA.
For all conditions, the full procedure spans 5 weeks in
total. Participants in the waiting-list condition will receive
one of the two treatments (by randomization) after the
waiting period, but the treatment data of these parti-
cipants will not be included into the main analyses. Three
and 6 months after treatment, participants will be con-
tacted by means of an automated email to complete the
online follow-up questionnaires. Participants who do not
complete the online questionnaires within 1 week will be
contacted via personalized emails and/or telephone calls.
When participants are unable to complete follow-up
assessments online, a hardcopy of the assessment, inclu-
ding a return envelope, will be mailed to them. If partici-
pants decide to discontinue study participation, efforts
will be made to retain them in the trial, while respecting
their right to withdraw from participation at any time
without any further consequences. Participants will not re-
ceive any monetary compensation for their involvement,
but treatment will be delivered free of charge.
Sequence generation and randomization
Treatment allocation will progress in accordance with
an electronically generated allocation sequence (https://
www.sealedenvelope.com/simple-randomiser/v1/lists).
The size of the allocation blocks (i.e., 3, 6, and 9) is ran-
domized, and eligible participants will be stratified accord-
ing to a present PTSD diagnosis to ensure that participants
with PTSD are distributed equally across conditions. The
allocation sequence will be stored with two independent
staff members who perform the randomization, and is con-
cealed from all researchers, therapists, and participants.
Measures
Demographics
Data on demographic variables such as age, gender, and
educational level will be collected for all participants.
Diagnostic measures
Diagnosis of nightmare disorder will be based on criteria for
nightmare disorder in the DSM-5 [1]. To determine the
presence of current comorbid Axis-I disorders, the Dutch
Structured Clinical Interview for DSM-IV-TR Axis-I dis-
orders (SCID-I; [54]) will be administered at pre- and post-
assessment. The reliability of the Dutch SCID-I is good, with
a mean inter-rater agreement of .71 (Cohen’s Kappa; [55]).
Treatment outcome measures
Treatment outcome measures will be assessed at baseline,
post-assessment, and 3- and 6-month follow-up. For an
overview of all assessments, see Table 1.
Table 1 Summary of measures
Measure Description T1 T2 T3 T4 T5 F1 F2
Primary outcome measures
NFQ Number of nightmares + + + + + + +
NDIQ Nightmare distress and impact + + + + + + +
Secondary outcome measures
NFQ Nights with nightmares + + + + + + +
ZIL PTSD symptoms + + + +
ISI Sleep complaints + + + +
NBQ Nightmare beliefs + + + +
Diagnostic measures
DSM-5 Nightmare disorder + +
SCID-I DSM-IV-TR Axis-I disorders + +
Mediators of change + + + + +
Imagery Exercise + + + + +
Note. T1 = Pre assessment, T2 = Week 1, T3 = Week 2, T4 = Week 3, T5 = Post
assessment, F1 = 3-month follow-up, F2 = 6-month follow-up. Mediators of
change are assessed at T + 1 day. DSM-5 = Diagnostic and Statistical Manual,
5th edition; ISI = Insomnia Sensitivity Index; NBQ = Nightmare Beliefs
Questionnaire; NDIQ = Nightmare Distress and Impact Questionnaire; NFQ =
Nightmare Frequency Questionnaire; SCID-I = Structured Clinical Interview for
DSM-IV-TR Axis-I disorders; ZIL = Zelf-Inventarisatie Lijst (Self-inventory List)
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Primary outcome measures
The first primary outcome measure addresses nightmare
frequency. There are two ways to measure nightmare fre-
quency with the widely used Nightmare Frequency Ques-
tionnaire (NFQ; [56]). This instrument assesses (1) the
number of nights with nightmares in the last week, and (2)
the total number of nightmares in the last week. As most
previous nightmare research is focused on the latter, rather
than the former conceptualization of nightmare frequency
(e.g., [11, 13]), the total number of nightmares in the last
week constitutes the first primary outcome measure, while
the number of nights with nightmares in the last week is
considered a secondary outcome measure. Both variables
are assessed by means of a one-question, self-report survey
(see NFQ; [56]).
The second primary outcome measure addresses dis-
tress caused by nightmares and the impact of nightmares
on everyday life as well as on sleep behavior, which is
assessed with a 12-item measurement instrument con-
structed for this study. For this purpose, several items of
the Nightmare Distress Questionnaire (NDQ; [57]) and
the Nightmare Effect Survey (NES; [58]) were modified
and served as a basis for the new survey. This newly de-
veloped Nightmare Distress and Impact Questionnaire
(NDIQ) consists of two subscales. The first subscale ad-
dresses the impact caused by nightmares during the day
(e.g., “Because of my nightmares, I cannot function
properly during the day”), while the second subscale is
focused on the distress caused by nightmares at night
(e.g., “My nightmares disturb my sleep pattern”). Given
that nightmares do not only cause sleep complaints, but
also severe daytime suffering, the authors aimed at con-
structing a questionnaire that could clearly distinguish
these two sources of nightmare distress. Items of the
NDIQ are scored on a four-point scale: 0 (Not), 1 (A little
bit), 2 (Somewhat), and 3 (Completely). Validation of this
questionnaire is still ongoing. The sumscore of both sub-
scales constitutes the second primary outcome measure,
while possible effects of IR and IE on the two subscales
will be explored separately.
Secondary outcome measures
The Zelf Inventarisatie Lijst (ZIL; [59]) will be used to
measure symptoms of posttraumatic stress disorder. The
ZIL is a 22-item Dutch self-report inventory covering the
severity of PTSD symptoms in the last 4 weeks. In contrast
to other measures of PTSD symptoms, the ZIL allows for
the assessment of posttraumatic symptoms irrespective of
the occurrence of a traumatic event. Given that the pro-
posed study aims to include participants with posttraumatic
as well as idiopathic nightmares, it is assumed that (at least)
some participants will not have experienced a traumatic
event. The ZIL, therefore, seems to be a suitable measure
of PTSD symptom severity in the present sample. The
reliability of the scale is good, with Cronbach’s α varying
from 0.90 to 0.94 [60], and a test-retest reliability of 0.92
[61].
Sleep complaints will be assessed with the Dutch version
of the Insomnia Severity Index (ISI; [62]). The English
questionnaire is a valid and reliable measure to detect
changes in insomnia severity (internal consistency = 0.78;
[63]). Validation studies on the Dutch version of this ques-
tionnaire are not yet published.
Dysfunctional beliefs about nightmares will be measured
with a newly developed Nightmare Beliefs Questionnaire
(NBQ). The NBQ was constructed based on nightmare
interviews with four pilot participants of the proposed
study. Given that dysfunctional beliefs have been shown to
play an important role in sleep disorders (e.g., [64]) as well
as other psychological disorders (e.g., [36, 65, 66]), it seems
worthwhile to construct a measure that can assesses such
dysfunctional beliefs about nightmares. The NBQ is a
15-item self-report questionnaire that measures the degree
to which patients hold certain beliefs about nightmares
(e.g., “People who suffer from nightmares are weak” or “I
cannot control my nightmares”). Items of the NBQ are
scored on a four-point scale: 0 (Not), 1 (A little bit), 2
(Somewhat), and 3 (Completely). Outcome values consist
of the sum of all items, which can range from 0 to 45. The
principal investigators (AK and JL) created the NBQ for the
purpose of the proposed trial. Validation of this question-
naire is still ongoing.
Other measures
To evaluate and monitor changes in the type of emotions
involved in nightmares over the course of treatment, par-
ticipants will be presented with a selection of emotions
commonly associated with nightmares (i.e., anxiety, anger,
sadness, shame, disgust, guilt, and helplessness). They are
asked to select the emotions they experienced during their
nightmare(s) and encouraged to write down any other
emotions they might have experienced.
If participants experienced one or more nightmares
during the previous week, they will be asked to fill out
four questions about the impact of the nightmare(s). On
four Visual Analog Scales (VAS) ranging from 0 (“not at
all”) to 100 (“very much”), participants are asked to indi-
cate the intensity of emotions during the nightmare(s), the
vividness of the nightmare(s), how often they awoke from
nightmare(s), and their sleep quality during the past week
(ranging from “very bad” to “very good”). In addition, all
participants are asked to indicate their average hours
of sleep during the past week. Note that all measures
reported here will be assessed weekly.
Mediators of change
In order to investigate temporal relationships between the
mediators and outcome measures in a methodologically
Kunze et al. Trials  (2016) 17:469 Page 7 of 14
well-considered manner [20, 67], the weekly appointments
and assessments will be separated by a minimum of 7 and
a maximum of 14 days. Proposed mediators of change
for the treatment effect of IR and IE are assessed 1 day
after each treatment session (and after pre- and post-
assessment). Participants are asked to fill out an online
questionnaire about their nightmares in general. This
questionnaire consists of seven VASs ranging from 0 (“not
at all” or “very bad”) to 100 (“very much” or “very good”),
which measure nightmare valence, predictability, control-
lability, and tolerability of emotions elicited by nightmares,
mastery of the nightmare content, sleep quality, and night-
mare distress. Between-session reductions in SUDs will be
assessed by means of the imagery exercise described below
(for an overview of the proposed mediators and their
corresponding items, see Table 2).
Imagery exercise
During baseline assessment, all participants will be asked
to identify a core nightmare, which will later be addressed
in treatment. Participants are instructed to choose a night-
mare that is highly emotional and part of a recurring
(emotional) nightmare theme (e.g., being killed, being
followed, losing someone, etc.). The core nightmare is
identified for several reasons: First, given that the present
treatment consists of three 60-min treatment sessions
only, it seems critical to identify the most distressing
nightmare(s) as early as possible in the treatment process.
Second, identifying and treating one particular nightmare
allows for the investigation of nightmare-specific treat-
ment effects. For this purpose, the core nightmare will be
used in a weekly imagery exercise at the beginning of each
treatment session. During the exercise, participants are
asked to briefly imagine their core nightmare as vividly as
possible until the emotions are sufficiently reactivated (ap-
proximately 1 − 3 min). Nightmare frequency, vividness,
and SUDs, as well as tolerability of negative emotions elic-
ited by the core nightmare, and the strongest emotion
experienced at the moment of nightmare reactivation are
being measured after nightmare reactivation. The night-
mare used in this exercise is subsequently addressed in
treatment. Note that while the exercise could be mistaken
for exposure, the main goal of the imagery exercise is to
reactivate the emotions sufficiently to address them in
treatment, instead of prolonged exposure to these emo-
tions (see also section “Imagery rescripting”).
Interventions
Both interventions (IR and IE) are written out in a detailed
treatment protocol that addresses the theoretical model,
treatment frame, and the use of treatment techniques. The
treatments consist of three individual 60-min sessions.
Within these sessions, approximately 40 min will be spent
on either exposure to or rescripting of the nightmare con-
tent. The remainder of the time will be used for filling out
questionnaires (± 10 min), introducing and preparing the
treatment exercises (± 5 min), and a short debriefing at
the conclusion of each session (± 5 min). Cognitive-
behavioral therapists with a completed Master’s degree-
level education in clinical psychology will deliver both
interventions. The therapists were trained by the authors
of the proposed study (AK, JL, NM, and AA) during two
4-h training sessions. The training involved assessment
and diagnosis of nightmare disorder, and a thorough
explanation of the present treatment protocol, including
sample treatments and exercises. After the waiting
period in the WL condition, treatment will be delivered by
trained but inexperienced therapists (baccalaureate
degree-level). The authors (AK and JL) will supervise
all therapists weekly. Treatment sessions will be
audio-recorded and independent judges blind for
treatment condition will rate a random selection of
audiotapes on treatment adherence.
In order to monitor treatment progress, therapists will
score participants’ nightmare vividness and SUDs, as well
as tolerability of negative emotions elicited by the current
nightmare image, and the strongest emotion experi-
enced at the conclusion of each IE or IR exercise. For
this purpose, therapists ask participants to indicate
the strength/severity of the above-named variables on
a scale from 0 (“not at all”) to 10 (“very much”) after
each exercise. While the number and duration of IE
and IR exercises within treatment sessions can differ
across individuals and sessions (approximately two to
four exercises during each treatment session), the
total number and duration of individual treatment ses-
sions will be the same between all participants (i.e., three
Table 2 Overview of proposed mediators
Mediator Item
Predictability of emotions “I think that I can predict the emotions
elicited by my nightmares.”
Controllability of emotions “I think that I can control the emotions
elicited by my nightmares.”
Tolerability of emotions “I think that I can tolerate the emotions
elicited by my nightmares.”
Mastery of nightmare content “I think that I am in control of the
content of my nightmares.”
Nightmare valence “When I think about my nightmares,
I get emotional.”
Nightmare distress “Nightmares have a negative influence
on my daily functioning.”
Sleep quality “How would you evaluate the quality
of last night’s sleep?”
Reduction in SUDs “How distressed do you feel right now?”
SUDs = Subjective Units of Distress
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60-min sessions; approximately 40 min spent on IE/IR).
Both interventions exclude homework assignments. Also,
in order to minimize possible demand effects, the explan-
ation of the treatment rationale is kept to a minimum (see
Additional file 2, for standardized treatment rationales).
Imagery rescripting
The IR protocol used in the proposed study is inspired by
the traditional IRT treatment protocols (e.g., [12]) as well
as a protocol for IR therapy for early childhood trauma
[68]. In contrast to more traditional IRT techniques, the
present protocol focuses exclusively on IR exercises. More
specifically, treatment components such as psychoeduca-
tion about sleep, nightmares, and mental imagery, as well
as keeping nightmare diaries and discussing nightmare
content were discarded. Instead, participants are intro-
duced to the rescripting technique immediately at the be-
ginning of the first treatment session. After reactivation of
the core nightmare, participants are instructed to change
the nightmare in any way they wish, as long as it leads to a
satisfying story. In contrast to traditional IRT and in line
with trauma-focused rescripting protocols (e.g., [68]),
participants are asked to actively change the nightmare in
their imagination. Thus, instead of first thinking about
how to change the nightmare and subsequently rehearsing
it, nightmares are changed directly after reactivation, while
the accompanying emotions are still accessible. Activation
of emotional memories seems to be necessary for the
adequate integration of corrective information to occur
[22]. Thus, in order for rescripting to be maximally suc-
cessful, it has been proposed that the negative emotions
accompanying an aversive event (e.g., nightmare) should
be sufficiently reactivated before rescripting [39, 69]. It is
important to discriminate between a short reactivation of
emotions (approximately 1–3 min) and prolonged expo-
sure, where patients are exposed to an aversive event
repeatedly and for a longer period of time (usually 45–
60 min). Thus, reactivation of an aversive event within
rescripting treatments is not considered to be exposure,
but a requisite component of the rescripting technique.
Within the present protocol, it is not essential to rehearse
a new nightmare script as often as possible, but rather to
fine-tune the new script in such a way that the negative
emotions accompanying the nightmare are maximally re-
duced until the participant is completely satisfied with the
new script and eventually feels at ease. This can be accom-
plished within one single rescripting exercise, but it might
also take multiple exercises (possibly across multiple ses-
sions) in order for the participant to rescript the original
nightmare in such a way that they feel entirely comfort-
able with the new nightmare script. Note that other night-
mares than the core nightmare may only be addressed in
treatment if rescripting of the core nightmare is success-
fully achieved early in the treatment process.
Imaginal exposure
The IE protocol used in the proposed study is based on a
standard IE intervention [70]. Contrary to other exposure-
based nightmare treatments, which are based on self-help
formats and might include other treatment components
such as nightmare diaries and relaxation exercises (e.g.,
[17, 19]), the current IE treatment consist of imaginal ex-
posure to the nightmare content only. More specifically,
after shortly reactivating the core nightmare, participants
are asked to vividly imagine the entire nightmare scenario
in their imagination and are encouraged to focus on and
experience all accompanying emotions. If necessary,
possible (cognitive) avoidance tendencies are shortly dis-
cussed to subsequently eliminate them. Similar to IR, par-
ticipants receive approximately 40 min IE in total during
each treatment session. However, individual IE exercises
can differ in length depending on the nightmare scenario,
the intensity of emotions elicited by the nightmare, and/or
on the level that participants are willing to fully commit to
the exercise. As for IR, exposure to nightmares other than
the core nightmare is only allowed if exposure to the core
nightmare has caused a substantial decrease of nightmare
distress early in the treatment process, and if the negative
emotions accompanied by the core nightmare are com-
pletely tolerable.
Data management and storage
All study-related data and other study material will be
stored securely at the study site (UvA PsyPoli). Participant
information and study data will be kept in locked cabinets
in areas with limited public access. After obtaining online
informed consent, participants will be allocated a unique
study identifier. A password-protected file that links par-
ticipants to their identifiers is stored on a secure server
hosted by the UvA. Any study material concerning partici-
pant information will not be released outside of the study
without written permission of the participant.
Data collected on paper during the trial will manually be
entered into a database. Self-report data collected online
(using an authorized UvA Qualtrics account) will be down-
loaded and added to the database. Data integrity will be
enforced through several ways, including valid values, range
checks and consistency checks. The password-protected
master database will be held on a secure server hosted by
the UvA, where only authorized trial personnel have access
to it. All obtained data and administrative forms (e.g.,
informed consent) will be stored in accordance with the
data storage protocol of the UvA Department of Psychology
(version January 2015).
Statistical methods
Outcome
Treatment effects will be analyzed on the intention-to-
treat principle with mixed regression. Fixed factors in the
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model will include: treatment condition, time, and their
interaction, as well as any relevant covariate that might re-
duce error. The covariance structure of the repeated part
will be determined by empirically assessing the best fitting
structure. If possible, random parts on the participant level
will be added. For the nightmare frequency outcomes,
mixed Poisson or negative binomial regression will be used.
For other outcomes standard mixed regression will be used,
assuming a normal distribution of residuals. If residuals
show a non-normal distribution, appropriate generalized
mixed models will be used (e.g., gamma regression in case
of skewed distributions).
Mediation
Mediators of the treatment effects for IR and IE will be
analyzed according to the following steps: (1) mediator
variables, which show a change during the course of
treatment, will be included in the statistical model. For
this purpose, the means across and within subjects over
time will be inspected for all eight proposed mediators.
In order to reduce the number of relevant mediator vari-
ables, we will inspect the association between the pro-
posed mediators over time. A composite score will be
calculated for those mediator variables that are highly
associated with each other if their theoretical
conceptualization allows for it. (2) In a series of separate
mixed regression analyses, statistically relevant mediator
variables will be selected from the remaining mediator
variables. To that end, the effect of each mediator on
treatment outcome will be explored regardless of treat-
ment condition. Each mediator score (measured the day
after pre-assessment and after all treatment sessions)
will be used to predict treatment outcome at the follo-
wing assessment (i.e., 6 days/nights later). (3) Only those
mediator variables that have an effect on treatment out-
come will subsequently be added to a final mixed regres-
sion model, taking treatment condition into account. Fixed
factors in the model will, therefore, include: treatment con-
dition (IE and IR), relevant mediators, time, and their inter-
action, as well as any relevant covariate that might reduce
error. The covariance structure of the repeated part will be
determined by empirically assessing the best fitting struc-
ture. If possible, random parts on the participant level will
be added. Note that if a mediator represents a working
mechanism, the strength of the association between medi-
ator and effect (i.e., outcome) should be similar in all con-
ditions [71]. Therefore, to investigate whether there is a
difference between the working mechanisms of IR and IE,
we will test whether the mean change for each mediator
differs between treatment conditions (i.e., the larger the
change, the more the treatment affects the mediator, indi-
cating that the working mechanism is strongly triggered by
the treatment). Also, we will inspect the percentage of vari-
ance of the clinical effect explained by each mediator, and
whether treatments differ in the percentage of variance
explained by a specific mediator. (4) In a last step, all pre-
viously determined relevant mediator variables will subse-
quently be tested with separate mediation analyses for IE
and IR (with WL as a reference group). Difference scores
of mediator assessments will be used to predict post-
assessment outcomes. Pre-treatment levels of the dependent
and mediator variables will be added to the model as covari-
ates (see also [64]). Both single and multiple mediation
analyses will be performed. Mediation will be tested by
evaluating the 95 % confidence interval of the indirect effect
(i.e., the effect of the intervention (IE or IR) on treatment
outcome through a specific mediator). For these analyses, we
will use bootstrapping [72, 73], a nonparametrical procedure
that produces an estimate of the sample distribution based
on several resamples. For the proposed analyses, a minimum
of n = 5000 bootstrap resamples will be generated. To the
best of our knowledge, bootstrap mediation is currently not
available for mixed regression. Unless such a technique is
available by the time of the analyses, we will execute the
bootstrap mediation test on the subsample with complete
data, as well as on the complete sample with missing values
imputed, to check for consistency of results. A multiple
imputation procedure based on 20 datasets will be used to
replacemissing values.
Discussion
With the proposed RCT, we aim to explore mechanisms of
change in rescripting-based and exposure-based treat-
ments for nightmare disorder. For this purpose, we intro-
duce adapted IR and IE treatment protocols for nightmare
disorder, each including one primarily active treatment
component (i.e., either rescripting of, or exposure to, the
nightmare content, respectively). Next to investigating the
efficacy of these stripped-down treatments when compared
to a waiting-list control condition, the research design
of the proposed study enables us to explore proposed
mediators of the treatment effect for IR and IE. Studying
mediators can offer important knowledge about the under-
lying working mechanisms of psychological treatments,
which might improve the effectiveness of everyday clinical
practice.
The study has several methodological strengths. First, it
follows the standard for evaluating the efficacy of psycho-
logical treatments (e.g., randomization of participants to
three conditions, including a waiting-list control condition,
allocation is concealed by means of randomization by in-
dependent staff members, post-assessment conducted by
blinded researchers). Second, the current research design is
well-suited to study mediators of change for the treatment
effect of IR and/or IE for nightmare disorder, which might
be a first step toward identifying possible mechanisms of
change for these treatments [20]. More specifically, measu-
ring several potential mediators simultaneously at multiple
Kunze et al. Trials  (2016) 17:469 Page 10 of 14
time points throughout the trial (i.e., preceding the inter-
mediate treatment effect assessments) allows us to establish
temporal as well as causal relationships between proposed
mediators and therapeutic outcome measures [20, 21].
Another advantage of the proposed study is its use of
stripped-down treatment formats. This method enables
us to gather relevant information about the efficacy of
specific treatment techniques (i.e., IR and IE) rather than
nonspecific treatment components (e.g., nightmare jour-
nals, relaxation exercises, extensive psychoeducation
about sleep and nightmares). Accordingly, the proposed
trial does not aspire to design the most efficacious treat-
ment package for nightmare disorder, but it rather aims to
investigate the efficacy of the separate treatment com-
ponents, and to explore differences and similarities in effi-
cacy and working mechanisms between rescripting-based
and exposure-based nightmare treatments. In order to
draw conclusions about the active component of night-
mare therapies, we find it important to study the two
treatment techniques in isolation. Once we have examined
the two techniques separately, future studies should con-
centrate on creating the optimal treatment package for
nightmare disorder.
The proposed study also has a number of weaknesses.
First, consistent mediator assessment might be compro-
mised by the logistical complexity of the study. More
specifically, while we aim at assessing treatment outcome
variables and mediators every 7 days, appointments might
sometimes be cancelled and/or rescheduled. In order to
maintain the temporal relationship between mediators
and outcome variable measurements as stable as possible,
appointments may only be (re)scheduled to a later time
point. Second, due to practical considerations, the pro-
posed study has a relatively small sample size. Therefore,
its statistical power might be too small to detect statis-
tically significant differences between IE and IR with re-
gard to treatment efficacy and/or mediators of change.
However, exploring potential differences between IE and
IR might inspire future research in this domain. Third, the
waiting-list period of the proposed study is rather short.
As a consequence, we cannot assess the long-term effects
of the stripped-down treatments. However, if the results
of the proposed trial support the efficacy of both interven-
tions, future research might directly compare the two
techniques as described in the present treatment protocol
to a waiting-list condition with a longer waiting period.
Fourth, two of the questionnaires used in the present
study have not yet been validated (NDIQ and NBQ). It
should be noted that the outcome variables used in night-
mare treatment studies often lack precise definitions. With
regard to nightmare research, it has become customary to
assess nightmare frequency and nightmare distress. Such
nightmare distress can be measured either in terms of dis-
tress directly associated with nightmares (e.g., NDQ [57]),
or in terms of the effects nightmares have on a person’s life
(e.g., NES [58]). While these questionnaires tap into differ-
ent constructs of nightmare distress, they also show some
considerable overlap. Therefore, we decided to create a
nightmare distress outcome measure (i.e., NDIQ), which
combines different aspects of nightmare distress in a single
questionnaire. We acknowledge that a lack of validation
might reduce confidence in the NDIQ as an outcome
measure. However, the NDIQ is constructed from items re-
sembling those of two validated questionnaires (NDQ and
NES). Given that the items included in the NDIQ are very
similar to those from these other questionnaires, we ex-
pect the NDIQ to be a valid and reliable measure. As to
the NBQ, it should be mentioned that dysfunctional night-
mare beliefs have not systematically been studied to date.
The NBQ, a novel questionnaire altogether, aims to assess
the occurrence of dysfunctional nightmare beliefs in night-
mare sufferers. It was constructed to resemble other vali-
dated dysfunctional beliefs questionnaires (e.g.,
Dysfunctional Beliefs and Attitudes about Sleep [74];
Panic Belief Inventory [75]; Metacognitions Questionnaire
[76]). To assess the psychometric properties of the NDIQ
and NBQ, prior to data analyses, both questionnaires will
be validated within a representative sample of nightmare
sufferers and healthy controls. Fifth, the selected media-
tors are assumed to play a crucial role in IE, IR, or both.
While we acknowledge that there are a multitude of
(other) proposed theories and processes underlying IE and
IR, we focus on those variables that have recently received
much attention in the empirical literature and that seem
especially relevant in the treatment of nightmares. Ac-
cordingly, it is possible that other relevant processes or
variables were disregarded.
Taken together, the proposed project offers a unique op-
portunity to investigate the efficacy of two core treatment
techniques for nightmares (IR and IE), and to explore and
identify their mechanisms of change. More specifically, by
including mediator and outcome variable assessments at
multiple time points throughout the study, we intent
to investigate temporal relationships between changes in
mediators and their effects on outcome measures, which
are needed to determine causal pathways of therapeutic
change. Thus, with the proposed trial, we aim to provide
new insights in the mechanisms of change of IR and IE
for nightmares and thereby contribute to the improve-
ment of such treatments. Moreover, given that rescripting
as well as exposure techniques are also used in the treat-
ment of other disorders, the results of the current study
might provide useful knowledge about the working mech-
anism of these therapeutic techniques in general.
Dissemination of results
The results of the proposed study are intended for publi-
cation in peer-reviewed journals independently of the
Kunze et al. Trials  (2016) 17:469 Page 11 of 14
outcome of the trial. The scientific output of the proposed
study will include at least one paper about the efficacy of
IE and IR, and one paper about the mechanisms of thera-
peutic change. Participants will be informed about the re-
sults of the study after publication by means of a Dutch
summary of the results.
Trial status
The first participant was enrolled in January 2015. Partici-
pant recruitment and enrollment is currently in the final
stage and is expected to continue until May 2016. Data
collection will proceed until the end of 2016.
Endnotes
1For the remainder of this article, the stripped-down
rescripting-based nightmare treatment will be called IR to
conceptually distinguish it from the currently widely used
imagery rehearsal therapy (IRT).
Additional files
Additional file 1: SPIRIT 2013 checklist. (PDF 121 kb)
Additional file 2: Treatment rationale of imaginal exposure (IE) and
imagery rescripting (IR) for nightmares. (PDF 67 kb)
Acknowledgements
We would like to thank Eline Bol, Nienke Dekker, Hanne Laan, Laura
Gerritsen, Jessie Kostermann, Nikki Kwee, Rojen Helbest, and
Laura Oomen for their assistance during the study. Furthermore,
we thank the UvA PsyPoli team for their dedication to the study.
Funding
This project is funded by grant 022.002.038 from the Netherlands
Organization for Scientific Research (NWO), awarded to the Dutch-Flemish
Postgraduate Research School for Experimental Psychopathology (EPP). The
funding source has no role in the study design and will not have any role
during data
collection and analysis, interpretation of the data, writing of the report(s),
or decision to submit results.
Availability of data and materials
Due to the status of the trial, supporting datasets are currently unavailable.
Authors’ contributions
AK, JL, NM, MK, and AA contributed to the design of the study. AK and JL
are the principal investigators and carry out recruitment and data collection.
AK, JL, NM, and AA wrote the treatment manual for the used interventions.
AK drafted the manuscript. All authors contributed to the writing of the
manuscript and approved the final manuscript.
Authors’ information
AK is a PhD candidate at the department of Clinical Psychology at the
University of Amsterdam. Her research is focused on the underlying
mechanisms of imagery rescripting therapy. JL is an assistant professor at the
University of Amsterdam, whose research focuses on sleep disorders. NM is
an assistant professor at the University of Amsterdam, whose research
focuses on the treatment of anxiety and mood disorders. MK is a professor
of experimental and clinical psychopathology; her research focuses on the
neurobiological and psychological processes of fear and anxiety. AA is a
professor of clinical psychology at the University of Amsterdam; his research
focuses on personality, anxiety and mood disorders and their treatment. The
research group has ample experience in conducting both experimental
research and clinical trials.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
The proposed study is registered at the Netherlands Trial Register (NTR4951),
and the Ethics Review Board of the University of Amsterdam (UvA) approved
the research protocol (2014-CP-3794). If applicable, important modifications
to the study protocol will be communicated to the Netherlands Trial Register
and Ethics Review Board of the UvA prior to implementation. Written
informed consent will be obtained from all participants.
Author details
1University of Amsterdam, Nieuwe Achtergracht 129-B, 1018 WS Amsterdam,
Netherlands. 2LMU Munich, Leopoldstraße 13, 80802 Munich, Germany.
3University of Münster, Fliednerstraße 21, 48149 Münster, Germany.
4Amsterdam Brain and Cognition, Nieuwe Achtergracht 129, 1018 WS
Amsterdam, Netherlands.
Received: 13 April 2016 Accepted: 24 May 2016
References
1. American Psychiatric Association. Diagnostic and statistical manual of mental
disorders. 5th ed. Washington, DC: American Psychiatric Association; 2003.
2. Nielsen T, Levin R. Nightmares: a new neurocognitive model. Sleep Med
Rev. 2007;11:295–310.
3. Spoormaker VI, Schredl M, van den Bout J. Nightmares: from anxiety
symptom to sleep disorder. Sleep Med Rev. 2006;10:19–31.
4. Schredl M. Dreams and nightmares in personality disorders. Curr Psychiatry
Rep. 2016;18:1–5.
5. Sandman N, Valli K, Kronholm E, Ollila HM, Revonsuo A, Laatikainen T, et al.
Nightmares: prevalence among the Finnish general adult population and
war veterans during 1972-2007. Sleep. 2013;36:1041–50.
6. Schredl M. Nightmare frequency in a representative German sample.
Eur Arch Psychiatry Clin Neurosci. 2010;260:565–70.
7. Spoormaker VI, van den Bout J. Depression and anxiety complaints;
relations with sleep disturbances. Eur Psychiatry. 2005;20:243–5.
8. Swart ML, van Schagen AM, Lancee J, van den Bout J. Prevalence of
nightmare disorder in psychiatric outpatients. Psychother Psychosom.
2013;82:267–8.
9. Lancee J, Spoormaker VI, Krakow B, van den Bout J. A systematic review of
cognitive-behavioral treatment for nightmares: toward a well-established
treatment. J Clin Sleep Med. 2008;4:475–80.
10. Augedal AW, Hansen KS, Kronhaug CR, Harvey AG, Pallesen S. Randomized
controlled trials of psychological and pharmacological treatments for
nightmares: a meta-analysis. Sleep Med Rev. 2013;17:143–52.
11. Hansen K, Höfling V, Kröner-Borowik T, Stangier U, Steil R. Efficacy of
psychological interventions aiming to reduce chronic nightmares:
a meta-analysis. Clin Psychol Rev. 2013;33:146–55.
12. Krakow B, Zadra A. Clinical management of chronic nightmares: imagery
rehearsal therapy. Behav Sleep Med. 2006;4:45–70.
13. Casement MD, Swanson LM. A meta-analysis of imagery rehearsal for
post-trauma nightmares: effects on nightmare frequency, sleep quality, and
posttraumatic stress. Clin Psychol Rev. 2012;32:566–74.
14. Krakow B, Hollifield M, Johnston L, Koss M, Schrader R, Warner TD, et al.
Imagery rehearsal therapy for chronic nightmares in sexual assault survivors
with posttraumatic stress disorder. JAMA. 2001;286:537–45.
15. Cellucci A, Lawrence P. The efficacy of systematic desensitization in
reducing nightmares. J Behav Ther Exp Psychiatry. 1978;9:109–14.
16. Miller WR, DiPilato M. Treatment of nightmares via relaxation and
desensitization: a controlled evaluation. J Consult Clin Psychol. 1983;51:870–7.
17. Burgess M, Gill M, Marks I. Postal self-exposure treatment of recurrent
nightmares: randomised controlled trial. Br J Psychiatry. 1998;172:257–62.
18. Grandi S, Fabbri S, Panattoni N, Gonnella E, Marks I. Self-exposure treatment
of recurrent nightmares: waiting-list-controlled trial and 4-year follow-up.
Psychother Psychosom. 2006;75:384–8.
Kunze et al. Trials  (2016) 17:469 Page 12 of 14
19. Lancee J, Spoormaker VI, van den Bout J. Cognitive-behavioral self-help
treatment for nightmares: a randomized controlled trial. Psychother
Psychosom. 2010;79:371–7.
20. Kazdin AE. Mediators and mechanisms of change in psychotherapy
research. Annu Rev Clin Psychol. 2007;3:1–27.
21. Kazdin AE. Understanding how and why psychotherapy leads to change.
Psychother Res. 2009;19:418–28.
22. Foa EB, Kozak MJ. Emotional processing of fear: exposure to corrective
information. Psychol Bull. 1986;99:20–35.
23. Foa EB, McNally RJ. Mechanisms of change in exposure therapy. In: Rapee
RM, editor. Curr Controv Anxiety Disord. New York: Guilford Press;
1996. p. 229–343.
24. Craske MG, Kircanski K, Zelikowsky M, Mystkowski J, Chowdhury N, Baker A.
Optimizing inhibitory learning during exposure therapy. Behav Res Ther.
2008;46:5–27.
25. Bouton ME. Context, time, and memory retrieval in the interference
paradigms of pavlovian learning. Psychol Bull. 1993;114:80–99.
26. Miller RR, Matzel LD. The comparator hypothesis: a response rule for the
expression of associations. In: Bower GH, editor. Psychol Learn Motiv.
San Diego, CA: Academic Press; 1988. p. 51–92.
27. Bouton ME, Mineka S, Barlow DH. A modern learning theory perspective on
the etiology of panic disorder. Psychol Rev. 2001;108:4–32.
28. Craske MG, Treanor M, Conway CC, Zbozinek T, Vervliet B. Maximizing exposure
therapy: an inhibitory learning approach. Behav Res Ther. 2014;58:10–23.
29. Bluett EJ, Zoellner LA, Feeny NC. Does change in distress matter?
Mechanisms of change in prolonged exposure for PTSD. J Behav Ther Exp
Psychiatry. 2014;45:97–104.
30. Vujanovic AA, Hart AS, Potter CM, Berenz EC, Niles B, Bernstein A. Main and
interactive effects of distress tolerance and negative affect intensity in
relation to PTSD symptoms among trauma-exposed adults. J Psychopathol
Behav Assess. 2013;35:235–43.
31. Karekla M, Forsyth JP, Kelly MM. Emotional avoidance and panicogenic
responding to a biological challenge procedure. Behav Ther. 2004;35:725–46.
32. Eifert GH, Heffner M. The effects of acceptance versus control contexts on
avoidance of panic-related symptoms. J Behav Ther Exp Psychiatry.
2003;34:293–312.
33. Hofmann SG. Cognitive processes during fear acquisition and extinction in
animals and humans: implications for exposure therapy of anxiety disorders.
Clin Psychol Rev. 2008;28:199–210.
34. Rotter JB. Generalized expectancies for internal versus external control of
reinforcement. Psychol Monogr. 1966;80:1–28.
35. Barlow DH. Anxiety and its disorders: the nature and treatment of anxiety
and panic. 2nd ed. New York: Guilford Press; 2002.
36. Clark DM. A cognitive approach to panic. Behav Res Ther. 1986;24:461–70.
37. Mineka S, Zinbarg R. A contemporary learning theory perspective on the
etiology of anxiety disorders: it’s not what you thought it was. Am Psychol.
2006;61:10–26.
38. Öhman A, Mineka S. Fears, phobias, and preparedness: toward an evolved
model of fear and fear learning. Psychol Rev. 2001;108:483–522.
39. Arntz A. Imagery rescripting as a therapeutic technique: review of clinical trials,
basic studies, and research agenda. J Exp Psychopathol. 2012;3:189–208.
40. Dibbets P, Poort H, Arntz A. Adding imagery rescripting during extinction
leads to less ABA renewal. J Behav Ther Exp Psychiatry. 2012;43:614–24.
41. Hagenaars MA, Arntz A. Reduced intrusion development after post-trauma
imagery rescripting; an experimental study. J Behav Ther Exp Psychiatry.
2012;43:808–14.
42. Long ME, Hammons ME, Davis JL, Frueh BC, Khan MM, Elhai JD, et al.
Imagery rescripting and exposure group treatment of posttraumatic
nightmares in veterans with PTSD. J Anxiety Disord. 2011;25:531–5.
43. Germain A, Krakow B, Faucher B, Zadra A, Nielsen T, Hollifield M, et al.
Increased mastery elements associated with imagery rehearsal treatment for
nightmares in sexual assault survivors with PTSD. Dreaming. 2004;14:195–206.
44. Spoormaker VI. A cognitive model of recurrent nightmares. Int J Dream Res.
2008;1:15–22.
45. Stickgold R, Walker MP. Sleep-dependent memory consolidation and
reconsolidation. Sleep Med. 2007;8:331–43.
46. Krakow B, Kellner R, Pathak D, Lambert L. Imagery rehearsal treatment for
chronic nightmares. Behav Res Ther. 1995;33:837–43.
47. Nappi CM, Drummond SPA, Thorp SR, McQuaid JR. Effectiveness of imagery
rehearsal therapy for the treatment of combat-related nightmares in
veterans. Behav Ther. 2010;41:237–44.
48. Krakow B, Zadra A. Imagery rehearsal therapy: principles and practice. Sleep
Med Clin. 2010;5:289–98.
49. Moore BA, Krakow B. Imagery rehearsal therapy for acute posttraumatic
nightmares among combat soldiers in Iraq. Am J Psychiatry. 2007;164:683–4.
50. Davis JL, Wright DC. Exposure, relaxation, and rescripting treatment for
trauma-related nightmares. J Trauma Dissociation. 2006;7:5–18.
51. Davis JL, Wright DC. Randomized clinical trial for treatment of chronic
nightmares in trauma-exposed adults. J Trauma Stress. 2007;20:123–33.
52. Chan A-W, Tetzlaff JM. Altman, Douglas G, Laupacis A, Gøtzsche PC,
Krleža-Jerić K, et al. SPIRIT 2013 Statement: defining standard protocol items
for clinical trials. Ann Intern Med. 2013;158:200–7.
53. Chan A-W, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin JA, et al.
SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical
trials. BMJ. 2013;346, e7586.
54. van Groenestijn MAC, Akkerhuis GW, Kupka RW, Schneider N, Nolen WA.
Gestructureerd klinisch interview voor de vaststelling van DSM-IV as-I
stoornissen (SCID-I) [Structured Clinical Interview for DSM-IV Axis I
Disorders]. Zwets & Zeitlinger: Lisse, The Netherlands; 1999.
55. Lobbestael J, Leurgans M, Arntz A. Inter-rater reliability of the Structured
Clinical Interview for DSM-IV axis I disorders (SCID I) and axis II disorders
(SCID II). Clin Psychol Psychother. 2011;18:75–9.
56. Krakow B, Schrader R, Tandberg D, Hollifield M, Koss MP, Yau CL, et al.
Nightmare frequency in sexual assault survivors with PTSD. J Anxiety Disord.
2002;16:175–90.
57. Belicki K. The relationship of nightmare frequency to nightmare suffering
with implications for treatment and research. Dreaming. 1992;2:143–8.
58. Krakow B, Hollifield M, Schrader R, Koss M, Tandberg D, Lauriello J, et al. A
controlled study of imagery rehearsal for chronic nightmares in sexual
assault survivors with PTSD: a preliminary report. J Trauma Stress.
2000;13:589–609.
59. Hovens JE, Bramsen I, van der Ploeg HM. Self-report inventory for the post-
traumatic stress disorder [Zelfinventarisatielijst voor de posttraumatusche
stressstoornis]. Tijdschrijft Klin Psychol. 2002;3:176–80.
60. Hovens JE, Bramsen I, van der Ploeg HM. Self-rating inventory for
posttraumatic stress disorder: review of the psychometric properties of a
new brief Dutch screening instrument. Percept Mot Skills. 2002;94:996–1008.
61. Hovens JE, van der Ploeg HM, Bramsen I, Reuling IEW. Test-retest reliability
of the self-rating inventory for posttraumatic stress disorder. Psychol Rep.
2000;87:735–7.
62. Morin CM. Insomnia: psychological assessment and management.
New York: Guilford Press; 1993.
63. Bastien CH, Vallieres A, Morin CM. Validation of the Insomnia Severity Index
as an outcome measure for insomnia research. Sleep Med. 2001;2:297–307.
64. Lancee J, Eisma MC, van Straten A, Kamphuis JH. Sleep-related safety
behaviors and dysfunctional beliefs mediate the efficacy of online CBT for
insomnia: a randomized controlled trial. Cogn Behav Ther. 2015;44:406–22.
65. Boden MT, John OP, Goldin PR, Werner K, Heimberg RG, Gross JJ. The role
of maladaptive beliefs in cognitive-behavioral therapy: evidence from social
anxiety disorder. Behav Res Ther. 2012;50:287–91.
66. Smith P, Yule W, Perrin S, Tranah T, Dalgleish T, Clark DM.
Cognitive-behavioral therapy for PTSD in children and adolescents:
a preliminary randomized controlled trial. J Am Acad Child Adolesc
Psychiatry. 2007;46:1051–61.
67. Murphy R, Cooper Z, Hollon SD, Fairburn CG. How do psychological treatments
work? Investigating mediators of change. Behav Res Ther. 2009;47:1–5.
68. Arntz A, Weertman A. Treatment of childhood memories: theory and
practice. Behav Res Ther. 1999;37:715–40.
69. Dibbets P, Arntz A. Imagery rescripting: is incorporation of the most aversive
scenes necessary? Memory. 2015;24:683–95.
70. Foa EB, Rothbaum BO. Behavioural psychotherapy for post-traumatic stress
disorder. Int Rev Psychiatry. 1989;1:219–26.
71. DeRubeis RJ, Evans MD, Hollon SD, Garvey MJ, Grove WM, Tuason VB.
How does cognitive therapy work? Cognitive change an symptom
change in cognitive therapy and pharmacotherapy for depression.
J Consult Clin Psychol. 1990;58:862–9.
72. Preacher KJ, Hayes AF. SPSS and SAS procedures for estimating indirect
effects in simple mediation models. Behav Res Methods Instrum Comput.
2004;36:717–31.
73. Preacher KJ, Hayes AF. Asymptotic and resampling strategies for assessing
and comparing indirect effects in multiple mediator models. Behav Res
Methods. 2008;40:879–91.
Kunze et al. Trials  (2016) 17:469 Page 13 of 14
74. Morin CM, Vallières A, Ivers H. Dysfunctional beliefs and attitudes about
sleep (DBAS): Validation of a brief version (DBAS-16). Sleep. 2007;30:1547–54.
75. Wenzel A, Sharp IR, Brown GK, Greenberg RL, Beck AT. Dysfunctional beliefs
in panic disorder: The Panic Belief Inventory. Behav Res Ther.
2006;44:819–33.
76. Wells A, Cartwright-Hatton S. A short form of the metacognitions
questionnaire: properties of the MCQ-30. Behav Res Ther.
2004;42:385–96.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Kunze et al. Trials  (2016) 17:469 Page 14 of 14
